Clinical Trial Update: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-775 evaluated lenvatinib plus pembrolizumab versus treatment of physician's choice in advanced endometrial cancer; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Endometrial Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17